Growth hormone secretagogues

IDrugs

Volumn 2, Issue 12, 1999, Pages 1302-1312

  Carpino, Philip A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000820911     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Iranmanesh A, Lizarralde G, Veldhuis JD: Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab (1991) 73:1081-1088.
2. Bertherat J, Bluet-Pajot MT, Epelbaum J: Neurocrine regulation of growth hormone. EUT J Endocrinol (1995) 132:12-24.
3. Bowers CY, Momany FA, Reynolds GA, Hong A: On the In vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology (1984) 114:1537-1545.
4. Momany FA, Bowers CY, Reynolds GA, Hong A, Newlander K: Conformational energy studies and in vitro and In vivo activity data on growth hormone-releasing peptides. Endocrinology (1984) 114:1531 -1536.
5. Bowers CY: Growth hormone-releasing peptide (CHRP). Cell Mol Life Sei (1998) 54:1316-1329.
6. Smith RG, Feighner ,S; Prendergast K, Guan X, Howard A: A new orphan receptor involved In pulsatile growth hormone release. -Trends Endocrinol Metab (1999) 10:128-135.
7. Ghlgo E, Arvat E, Camanni F: Orally active growth hormone secretagogues: state of the art and clinical perspectives. Ann Med (Helsinki) (1998) 30:159-168.
8. Smith RG, Van der Ploeg LHT, Howard, AD, Feighner SD, Kang C, Hickey GJ, Wyvratt MJ, Fisher MH, Nargund RP, Patchen AA: Peptldomimetic regulation of growth hormone secretion. Endocr Rev (1997) 18:621-645.
9. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, et ah A receptor in pituitary and hypothalamus that functions in growth hormone release. Science (1996) 273:974-977.
10. McKee KK, Palyha OC, Feighner SD, Hreniuk, DL, Tan CP, Phillips MS, Smith RG, Van der Ploeg LHT, Howard AD: Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol Endocrinol (1997)11:415-423.
11. Cheng K, Chan WWS, Butler B, Barretto A, Smith RG: Evidence for a role of protein kinase-C in His-D-Trp-Ala-Trp-WheLys-NH2-induced growth hormone release from rat primary pituitary cells. Endocrinology (1991) 129:3337-3342.
12. Dickson SL, Leng G, Robinson ICAF: Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons. Neuroscience (1993)53:303-306.
13. Bailey ART, Smith RG, Leng G: The nonpeptide growth hormone secretagogue, MK-0677, activates hypothalamic arcuate nucleus neurons in vivo. J Neuroendocrinol (1998) 10:111-118.
14. Smith RG, Pong S-S; Hickey G, Jacks T, Cheng K, Leonard R, Cohen CJ, Arena JP, Chang CH, Drisko J, Wyvratt M, Fisher M, Nargund R, Patchett A: Modulation of pulsatile GH release through a novel receptor In hypothalamus and pituitary gland. In: Recent Prog Horn Res, Endocrine Society, Bethesda, MD (1996) 51:261-286.
15. Conley LK, Teik JA, Deghenghi R, Imbimbo BP, Giustina A, Locatelli V, Wehrenberg WB: Mechanism of action of Hexarelin and GHRP-6: Analysis of the involvement of GHRH and somatostatin in the rat Neuroendocrinology (1995)61:44-50.
16. Clark RG, Cartsson LMS, Trojnar J, Robinson 1C: The effects of a growth hormone-releasing peptide and growth hormone-releasing factor in conscious and anesthetized rats. J Neuroendocrinol (1989) 1:249-55.
17. Pandya N, Demott-Friberg R, Bowers CY, Barkan AI, Jaffe CA: Growth hormone (GH)-Releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab (1998) 83:1186-1189.
18. Maheshwari HG, Rahim A, Shalet SM, Baumann G: Selective lack of growth hormone (GH) response to the GH-releasing peptide hexarelin In patients with GH-releasing hormone receptor deficiency. J Clin Endocrinol Metab (1999) 84: 956-959.
19. Pombo M, Barreiro J, Penalva A, Peino R, Dieguez C, Casanueva FF: Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transaction. J Clin Endocrinol Metab (1995) 80:180-184.
20. Goth Ml, Lyons CE, Canny BJ, Thomer MO: Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology (1992) 130:939-944.
21. Mickey G J, Jacks TM, Schleim K-D, Frazier E, Chen HY, Krupa D, Feeney W, Nargund RP, Patchett AA, Smith RG: Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles. J Endocrinol (1997)152:183-192.
22. Jacks T, Hickey G, Judith F, Taylor J, Chen H, Krupa D, Feeney W, Schoen W, Ok D, Fisher M, Wyvratt M, Smith R: Effects of acute and repeated intravenous administration of L-692585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. J Endocrinol (1994) 143:399-406.
23. Nijland EA, Strasburger CJ, Popp-Snijders C, Van Der Wal PS, van der Veen EA: A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-! secretion in healthy young men. Eur J Endocrinol (1998) 139:395-401.
24. Ghigo E, Arvat E, Gianotti L, Di Vito L, Broglio F, Muccioli G, Camanni F: Endocrine response to growth hormonereleasing peptides across human life span. In: Growth Horm Secretagogues Clin Pract [Int Symp GH Secretagogues Meeting Date 1997]. Bereu BB, Walker RF (Eds), Marcel Dekker, New York (1998): 345-367.
25. Arvat E, Di Vito L, Maccagno B, Broglio F, Boghen F, Deghenghi R, Camanni F, Ghigo E: Effects of GHRP-2 and Hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides (1997) 18:885-891.
26. Massoud AF, Hindmarsh PC, Brook CGD: Hexarelin-induced growth hormone, cortisol, and prolactin release: a doseresponse study. J Clin Endocrinol Metab (1996) 81:4338-4341.
27. Thomas GB, Fairhall KM, Robinson ICAF: Activation of the hypothalamo-pituitary-adrenal axis by the growth hormone (GH) secretagogue, GH-releasing peptide-6, In rats. Endocrinology (1997) 138:1585-1591.
28. Ghigo E, Arvat E, Camanni F: Growth hormone Secretagogues as corticotropin-releasing factors. Growth Horm IGF Res (1998) 8(Suppl B):145-148. '
29. Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH: Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol (1998) 139:552-561.
30. Kerkhofs M, Van Cauter E, Onderbergen V, Gaufriez A, Thorner MO, Copinschi G: Sleep-promoting effects of growth hormone-releasing hormone in normal men. Am J P/jys/o/(1993) 264(4, Pt 1):E594-E598.
31. Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RG: Effects of single nightly injections of growth hormone-releasing hormone (GHRH 129) In healthy elderly men. Metab Clin Exp (1997) 46:89-96.
32. Russell-Jones DL, Weissberger AJ: The role of growth hormone in the regulation of body composition in the adult. Growth flegu/(1996) 6:247-252.
33. Verfielst J, Abs R, Vandeweghe M, Mockel J, Legros JJ, Copinschi G, Mahler C, Velkeniers B, Vanhaelst L, Aelst AV, De Rijdt D, Stevenaert A, Beckers A: Two years of replacement therapy in adults with growth hormone deficiency. Clin Endocrinol (1997) 47(4):485-494.
34. Isgaard J, Tivesten A, Friberg P, Bengtsson BA: The role of the GH/IGF-I axis for cardiac function and structure. Horm Metab Res (1999) 31:50-54.
35. Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP, Wang J, Bozzette SA, Breitmeyer JB: Recombinant human growth hormone in patients with HIV-associated wasting; a randomized, placebo-controlled trial. Ann Intern Med (1996) 125:873-882.
36. Jorgensen PH: Growth hormone, skin and wound healing experimental studies in the rat. Acta Pathol Microbiol Immunol Scand (1997) 72(Suppl):1 -54.
37. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE: Effects of human growth hormone in men over 60 years old. New Engl J Med (1990) 323:1-6.
38. Papadakis MA, Grady D, Black D, Tiemey MJ, Gooding GAW, Schambelan M, Grunfeld C: Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med (1996) 124:708-716.
39. Patchett AA, Nargund RP, Tata JR, Chen M-H, Barakat KJ, Johnston DB, Cheng K, Chan WW-S, Butler B, Hickey G, Jacks T, Schleim K, Pong SS, Chaung LYP, Chen HY, Fraziert E, Leung KH, Chiu SHL, Smith RG: Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sei USA (1995)92:7001-7005.
40. Jacks T, Smith R, Judith F, Schleim K, Frazier E, Chen H, Krupa D, Hora Jr D, Nargund R, Patchett A, Hickey G: MK0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology (1996) 137:5284-5289.
41. Copinschi G, van Onderbergen A, L'Hermite-Balériaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thomer MO, Van Cauter E: Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab (1996) 81:2776-2782.
42. Chapman IM, Pescovitz OH, Murphy G, Treep T, Cerchio KA, Krupa D, Gertz B, Polvino WJ, Skiles EH, Pezzoli SS.'Thomer MO: Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-) axis in selected GH-deficient adults. J Clin Endocrinol Metab (1997) 82:3455-63.
43. Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Vêldhuis JD, Gormley GJ, Thomer MO: Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) In healthy elderly subjects. J din Endocrinol Metab (1996) 81:4249-4257.
44. Yu H, Cassorta F, Tiulpakov A, Shi Y-F, Setian N, Bereu B, Arango A, Kletter G, Pescovitz O, DiMartino J, Krupa D, Cambria M, Kanojia P, Bach MA: A double blind placebocontrolled efficacy trial of an oral growth hormone (GH) secretagogue (MK-0677) in GH-deficient (GHD) children. Annu Meet Endocrine Soc (1998) 80 New Orleans OR24-6.
45. Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR: MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab (1998) 83:320-325.
46. Svensson J, Lonn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjostrom L, Bengtsson BA: Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab (1998) 83:362-369.
47. Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson BA: Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone résorption in obese young males. J Bone Miner Res (1998) 13:1158-66.
48. Copinschi G, Leproult R, Van Onderbergen A, Gaufriez A, Cole KY, Schilling LM, Mendel CM, De Lepeleire l, Bolognese JA, Van Cauter E: Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology (1997) 66:278-86.
49. Raun K, Andersen PH, Ankersen M, Hansen BS, Hansen TK, Johansen NL, Johansen PB, Lau J, Lundt B, Nielsen KK, Madsen K, Pesko B: NNC26-0703, an orally active specific growth hormone secretagogue. Growth Hormone Research Society (GRS) (1998) San Francisco O-06.
50. Johansen PB, Haahr P-M, Malmlof K, Rasmussen LG, Rau HC, Wilken M: Biological effects in rats of NNC 26-0703, a new oral growth hormone secretagogue. Growth Hormone Research Society (GRS) (1998) San Francisco P-07.
51. Carpino PA, Lefker BA, Toler SM, Pan LC, Cook ER, DiBrino JN, Hada WA, Inthavongsay J, Mangano FM, Mullins MA, Nickerson DF, Ragan JA, Rose CR, Tess DA, Wright AS, Zawistoski MP, Pine CM, Cnidsey-Frink K, Ng OC, DaSilva-Jardine P, Thompson DD: Design, synthesis and biological evaluation of a novel series of pyrazolidone-piperidine growth hormone secretagogues. ACS (1998) 216 Boston MEDI276.
52. Pan LC, Carpino PA, Lefker BA, Pirie CM. Chidsey-Frink K, Ng OC, MacLean DB, Pettersen JC, Thompson DD: CP-424,391: A novel orally active growth hormone secretagogue in rats and dogs. Annu Meet Endocrine Soc (1998) 80 New Orleans P2-190.
53. Schoen WR, Pisano JM, Prendergast K, Wyvratt MJ Jr, Fisher MH, Cheng, K, Chan WW-S, Butler B, Smith RG, Ball RG: A novel 3-substituted benzazeplnone growth hormone secretagogue (L-692429). J Med Chern (1994) 37:897-906.
54. Leung KH, Cohn DA, Miller RR, Doss GA, Steams RA, Simpson RE, Feeney WP, Chiu SHL: Pharmacokinetics and disposition of L-692429. A novel nonpeptidyl growth hormone secretagogue in preclinical species. Drug Metab Dispos (1996) 24:753-760.
55. Chapman IM, Hartman ML, Pezzoli SS, Thomer MO: Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692429, in older adults - A clinical research center study. J Clin Endocrinol Metab (1996) 81:2874-2880.
56. Kirk SE, Gertz BJ, Schneider SH, Hartman ML, Pezzoli SS, Wittreich JM, Krupa, David A, Seibold JR, Thomer MO: Effects of obesity and feeding '. on the growth hormone (GH) response to the GH secretagogue L-692429 in young men. J Clin Endocrinol Metab (1997) 82:1154-1159.
57. Bowers CY: GH releasing peptides-structure and kinetics. J Pediatr Endocrinol (1993) 6:21-31.
58. Pihoker C, Keams GL, French D, Bowers CY: Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study In children. J Clin Endocrinol Metab (1998) 83:1168-1172.
59. Mericq V, Cassorta F, Salazar T, Avila A, Iniguez G, Bowers CY, Merriam GR: Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab (1998) 83: 2355-2360.
60. Conley LK, Giustina A, Imbimbo BP, Stagg LC, Deghenghi R, Wehrenberg WB: Hexarelin [His-D-2-Methyl-Trp-Ala-Trp-DPhe-Lys-NHJ, a new GH-releasing peptide, is biologically active in male and female rats. Endocrine (1994) 2:691-695.
61. Bellone J, Bartolotta, E, Sgattoni C, Aimaretti G, Arvat E, Bellone S, Deghenghi R, Ghigo E: Hexarelin, a synthetic GHreleasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not In prepubertal children and in elderly subjects. J Endocrinol Invest (1998) 21:494-500.
62. Rahim A, O'Neill PA, Shalet SM: Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab (1998)83:1644-1649.
63. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A: Intranasal administration of the CHRP hexarelin accelerates growth in short children. Clin Endocrinol (1995) 43:631-5.
64. Bisi G, Podio V, Valetta MR, Broglio F, Bertuccio G,; Del Rio G, Arvat E, Boghen MF, Deghenghi R, Muccioli G, Ong H, GhigoE: Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest (1999) 22:266-272.
65. Chang CH, Rickes EL, McGuire L, Frazier E, Chen H, Barakat K, Nargund R, Patchett A, Smith RG, Hickey GJ: Growth hormone (GH) and insulin-like growth factor I responses after treatments with an orally active GH secretagogue L-163,255 in swine. Endocrinology (1996) 137:4851-4856.
66. Lieber RL, Jacks TM, Monier RL, Schleim K, Haven M, Cuizon D, Gershuni DH, Lopez MA, Hora Jr D, Nargund R, Feeney W, Hickey GJ: Growth hormone secretagogue increases muscle strength during remobilization after canine hindlimb immobilization. J Orthop Res (1997) 15:519-527.
67. Chang CH, McNamara LA, Rickes EL, Zhang. D, Mariano M, Hora D, Cunningham P, Feeney W, Prahalada S, Bach M, Smith RG, Mickey GJ: Chronic treatment with GH secretagogue L-163,255 and dexamethasone alone or In combination, on body weight, body composition, and serum chemistry including IGF-1 in mongrel dogs. Annu Meet Endocrine Soc (1998) 80 New Orleans P1-187.
68. Yang L, Morriello G, Patchett AA, Leung K, Jacks T, Cheng K, Schleim KD, Feeney W, Chan, WW-S, Chiu S-HL, Smith RG: 1 -[2(RH2-Amino-2-methylpropionylamino)-3-{1 H-indol-3yl)propionyl]-3-benzylpiperidine-3(S)-carboxylic acid ethyl ester (L-163,540): a potent, orally bioavailable, and shortduration growth hormone secretagogue. J Med Chem (1998)41:2439-2441.
69. DeVita RJ, Bochis R, Frontier AJ, Kotliar A, Fisher MH, Schoen WR, Wyvratt MJ, Cheng K, Chan WWS, Butler B, Smith RG, Jacks TM, Hickey GJ, Schleim KD, Leung K, Chen 2, Chiu SHL, Feeney WP, Cunningham PK: A potent, orally bioavailable benzazepinone growth hormone secretagogue. J Med Chem (1998) 41:1716-1728.
70. ELI LILLY AND COMPANY (Dodge JA, Hauser KL, Heiman ML, Jones SA, Alt CA, Bryant HU, Cohen JD, Copp JD, Fahey KJ, Gritton WH, Jungheim LN, Kennedy JH, Lugar CW III, Muehl BS, Palkowitz AD, Ratz AM, Rhodes GA, Robey RL, Seyler DE, Shepherd TA, Thrasher KJ, Trankle WG): Preparation of heterocyclic peptide derivatives as growth hormone secretagogues. WO-09908699 (1999).
71. ELI LILLY AND COMPANY (Kauffman R, Palkowitz A): Treatment of congestive heart failure with growth hormone secretagogues. WO-09908697 (1999).
72. KAKEN PHARMACEUTICAL Co LTD (Funamazi H, Ishiyama N): Novel amide derivatives and their use as growth hormone releasing factors. WO-09909991 (1999).